CorVista System with PH Add-On vs Cleerly ISCHEMIA

Tool A, the CorVista System, offers a highly non-invasive, point-of-care diagnostic experience that requires no radiation, contrast agents, injections, fasting, or exercise, providing rapid results within minutes via a secure web portal. This significantly reduces patient burden and simplifies the clinical workflow at the point of care. Tool B, Cleerly ISCHEMIA, while non-invasive in terms of not requiring surgery, still necessitates a CCTA scan, which involves radiation and contrast, making Tool A more broadly user-friendly for patients and diverse clinical settings.

Both tools are FDA-cleared and clinically validated. However, Cleerly ISCHEMIA provides a more comprehensive and granular assessment by analyzing CCTA scans to determine vessel-level ischemia likelihood, non-invasive fractional flow reserve (FFR) estimation, and detailed coronary plaque characterization (volume, type, location). Its validation in trials like CREDENCE and PACIFIC against invasive FFR as the gold standard, and its prognostic utility for future MACE events, demonstrate a deeper clinical insight crucial for personalized diagnosis and treatment planning.

While both tools require direct contact for pricing, Cleerly ISCHEMIA has a significant advantage in pricing and value due to its established Category I CPTu00ae Code 75580 for non-invasive FFR estimation, effective January 1, 2024. This CPT code provides a clear pathway for reimbursement, with an established Medicare allowable rate for hospital outpatient settings, which enhances its financial viability and ease of adoption for healthcare providers.

Both tools are cloud/web-based, HIPAA compliant, and likely offer Business Associate Agreements (BAAs). However, Cleerly ISCHEMIA explicitly highlights 'Integration with PowerScribe via API' as a key feature. This direct integration into a widely used radiology reporting system makes Tool B more readily adaptable and integrated into existing enterprise healthcare IT infrastructures and clinical workflows, particularly for imaging centers and hospitals.

Both tools demonstrate significant innovation in cardiovascular AI. However, the CorVista System's innovation lies in its fundamentally different approach to data acquisition: a completely non-invasive, point-of-care diagnostic platform that uses machine-learned algorithms to analyze cardiac and hemodynamic signals without radiation, contrast agents, injections, fasting, or exercise. This novel method of assessment, coupled with its FDA Breakthrough Device designation for PH, represents a more disruptive innovation in patient convenience and accessibility.

Cleerly ISCHEMIA offers a more transparent and comprehensive suite of public-facing support and documentation resources. Its website provides a dedicated support contact page, patient education materials, FAQs, billing guidelines, coverage information, and webinars that discuss training and imaging protocols. In contrast, specific public-facing support portals or detailed documentation for the CorVista System were not readily available in the search results.